- Home
- CLCO vs RZLT Comparison
CLCO vs RZLT Comparison
Compare CLCO & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLCO
- RZLT
- Stock Information
- Founded
- CLCO 2018
- RZLT 2010
- Country
- CLCO United Kingdom
- RZLT United States
- Employees
- CLCO N/A
- RZLT N/A
- Industry
- CLCO
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- CLCO
- RZLT Health Care
- Exchange
- CLCO Nasdaq
- RZLT Nasdaq
- Market Cap
- CLCO 353.6M
- RZLT 361.3M
- IPO Year
- CLCO N/A
- RZLT N/A
- Fundamental
- Price
- CLCO $7.02
- RZLT $4.10
- Analyst Decision
- CLCO
- RZLT Strong Buy
- Analyst Count
- CLCO 0
- RZLT 6
- Target Price
- CLCO N/A
- RZLT $12.00
- AVG Volume (30 Days)
- CLCO 119.4K
- RZLT 815.9K
- Earning Date
- CLCO 05-21-2025
- RZLT 05-13-2025
- Dividend Yield
- CLCO 8.57%
- RZLT N/A
- EPS Growth
- CLCO N/A
- RZLT N/A
- EPS
- CLCO 1.31
- RZLT N/A
- Revenue
- CLCO $320,759,000.00
- RZLT N/A
- Revenue This Year
- CLCO $2.03
- RZLT $35.39
- Revenue Next Year
- CLCO N/A
- RZLT N/A
- P/E Ratio
- CLCO $5.23
- RZLT N/A
- Revenue Growth
- CLCO N/A
- RZLT N/A
- 52 Week Low
- CLCO $4.51
- RZLT $2.22
- 52 Week High
- CLCO $12.45
- RZLT $6.19
- Technical
- Relative Strength Index (RSI)
- CLCO 59.90
- RZLT 50.40
- Support Level
- CLCO $6.68
- RZLT $4.10
- Resistance Level
- CLCO $7.50
- RZLT $4.56
- Average True Range (ATR)
- CLCO 0.28
- RZLT 0.25
- MACD
- CLCO 0.00
- RZLT -0.05
- Stochastic Oscillator
- CLCO 59.66
- RZLT 11.48
About CLCO Cool Company Ltd.
Cool Co Ltd is a LNG shipping company. The company is engaged in the acquisition, ownership, operation and chartering of liquefied natural gas (LNG) carriers (LNGCs), and the operation of third party fleets under management agreements. The company manages its business through a single operating and reporting segment, the LNG carrier market.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.